OncoSwab Co.

OncoSwab Co. has developed a simple noninvasive nasal fluid test that analyzes small amounts of nasal fluid (<0.5mL) obtained via a swab for the presence of a wide array of genetic markers. Their first use case is early detection of lung Cancer. Presently, up to 90% of the lung biopsies ordered for patients after imaging are negative for cancer, and newer blood-based screening tests require cancer cells to enter the bloodstream (limited in the early stage of lung cancer). Oncoswab’s test delivers accurate results fast (days) to reduce the need to order unnecessary biopsies and preliminary tests of nasal fluid from early-stage lung cancer patients detect up to 20x higher DNA concentrations than in the equivalent volume of blood. Oncoswab’s test is easy to administer without specialized medical personnel, improving access and closing the gap between lung cancer detection and first intervention.